Mylan Reports Third Quarter Adjusted Diluted EPS of $0.32

Mylan Raises 2009 Adjusted Diluted EPS Guidance Range to $1.24 - $1.28

PITTSBURGH, Oct. 29 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today
announced its financial results for the three and nine months ended September
30, 2009.

Financial Highlights

-- Adjusted diluted EPS of $0.32 and $0.97 for the three and nine months
ended September 30, 2009, compared to $0.23 and $0.52 for the same
prior
year periods;
-- Total revenues of $1.26 billion for the three months ended September
30,
2009;
-- Total revenues of $3.74 billion for the nine months ended September
30,
2009;
-- On a GAAP basis, a loss per diluted share of $0.13 for the three
months
ended September 30, 2009;

-- On a GAAP basis, earnings per diluted share of $0.29 for the nine
months
ended September 30, 2009.

Mylan's Chairman and CEO Robert J. Coury commented: "I am particularly pleased
with these results in light of the fact that they were achieved through higher
volumes, market growth, and multiple new product launches across the globe and
not from any one product. This is clearly indicative of the efficient,
globally diverse business model that we've created and is reflective of our
operators' continued exemplary execution that has led to the accelerated
realization of our integration-related synergies."

Coury continued: "We are increasing the range of our full year 2009 adjusted
diluted EPS guidance to $1.24 - $1.28, and we are confident that this momentum
will continue into 2010 and enable us to once again deliver the revenue and
earnings performance growth that we envision."

Financial Summary

Mylan previously had three reportable segments, "Generics," "Specialty" and
"Matrix." The Matrix segment had consisted of Matrix Laboratories Limited,
which had been a publicly traded Indian Company in which Mylan held a 71.2%
ownership stake. Beginning this quarter, Mylan has re-evaluated its segment
disclosure. Following the acquisition of approximately 24% of the remaining
interest in Matrix and the related de-listing, Mylan will report two segments,
"Generics" and "Specialty". The former Matrix Segment is included within the
Generics Segment. Information for earlier periods has been recast for
comparability.

Total revenues for the quarter ended September 30, 2009 were $1.26 billion
compared to $1.66 billion for the three months ended September 30, 2008.
Included in total revenues for the three months ended September 30, 2008, was
$455.0 million of revenue related to the Company's sale of the product rights
of Bystolic(TM). Excluding this, total revenues increased by $62.2 million or
5.2% over the same prior year period. Excluding the unfavorable effect of
foreign currency translation, primarily reflecting a stronger U.S. dollar,
year-over-year revenue growth on a constant currency basis would have been
approximately 9%.

Generics revenues, which are derived from sales in North America, Europe, the
Middle East and Africa (collectively, EMEA), and Asia Pacific were $1.12
billion in the current quarter, compared to $1.08 billion in the same prior
year period.

Total revenues from North America were $502.5 million for the three months
ended September 30, 2009, compared to $460.3 million for the same prior year
period, representing an increase of 9.2%.

Revenues from products launched in North America subsequent to September 30,
2008, and increased volume were primarily responsible for the increase in
revenues, partially offset by unfavorable pricing as a result of additional
generic competition on certain products. New products contributed revenues of
approximately $60.0 million.

Total revenues from EMEA were $417.6 million in the current quarter, compared
to $422.1 million in the same prior year period, a decrease of 1.1%. On a
constant currency basis, EMEA revenues increased by approximately 7% over the
prior year period. Higher revenues in France, EMEA's largest market, and the
U.K. served to offset lower revenue in Germany. In France, revenues increased
as a result of higher volumes and new product launches, while prior period
revenues in the U.K. were negatively impacted by excess supply that existed in
the market at that time.

Sales in Asia Pacific are derived from Mylan's operations in Australia, India,
Japan and New Zealand. Asia Pacific revenues were $237.0 million in the
current quarter, compared to $226.6 million in the same prior year period, an
increase of 4.6%. On a constant currency basis, sales increased approximately
10%, with increased sales in Japan and India offsetting lower revenues in
Australia. Also contributing to the increase in Asia Pacific revenues are
higher third-party sales of active pharmaceutical ingredients (API). API is
also sold to Mylan subsidiaries in conjunction with the Company's vertical
integration strategy.

Specialty, consisting of Mylan's Dey business, which focuses on the
development, manufacture and marketing of specialty pharmaceuticals in the
respiratory and severe allergy markets, reported third party revenues of
$150.9 million, an increase of 20.3% from third party revenues of $125.4
million for the three months ended September 30, 2008. Perforomist® Solution,
Dey's Formoterol Fumarate Inhalation Solution (Perforomist Solution), and
Dey's EpiPen® Auto-Injector (EpiPen Auto-Injector), were the primary drivers
of the increase in revenues.

Consolidated gross profit for the three months ended September 30, 2009, was
$505.0 million and gross margins were 39.9%, compared to gross profit of
$911.1 million and gross margins of 55.0% in the same prior year period, which
included the impact of the sale of Bystolic. Gross profit in both periods is
negatively impacted by certain purchase accounting related items totaling
$71.8 million and $105.4 million for the quarters ended September 30, 2009 and
2008, which consisted primarily of incremental amortization related to
purchased intangible assets. Excluding these amounts from both periods and
the impact of Bystolic from the prior year, gross margins were 45.6% in the
current year compared to 46.7% in the prior.

Earnings from operations were $61.3 million for the three months ended
September 30, 2009, compared to $560.8 million for the same prior year period.
During the three months ended September 30, 2009, the Company recorded net
unfavorable litigation charges of $114.3 million. Included in this amount was
a one time, non-recurring, charge of $121.0 million ($83.0 million after-tax)
related to the previously announced settlement of an investigation by the U.S.
Department of Justice concerning calculations of Medicaid drug rebates.
Excluding litigation, as well as the impact of the Bystolic revenue in 2008
and the purchase accounting related items in both periods, as mentioned above,
earnings from operations were $247.4 million compared to $211.3 million, an
increase of $36.1 million or 17.1% over the prior year. This increase in
operating income in the current quarter is due to increased sales and gross
profit, as well as lower R&D and SG&A expense. R&D expense decreased by $4.9
million in the current quarter, primarily in Generics, and is reflective of
certain restructuring activities undertaken by the Company with respect to the
previously announced rationalization and optimization of the global
manufacturing and research and development platforms. SG&A expense decreased
by $16.0 million in the quarter primarily due to lower costs, including
temporary staffing and consulting, related to the integration of the former
Merck Generics business, with the majority of such costs having been incurred
in the prior year. Additionally, both SG&A and R&D expense in the current
quarter were favorably impacted by the effect of the stronger U.S. dollar.

Interest expense for the three months ended September 30, 2009, totaled $77.0
million compared to $93.5 million for the three months ended September 30,
2008. The decrease is due to the reduction of our outstanding debt balance,
through repayments made in December 2008 and March 2009, as well as lower
overall interest rates. Other income, net, for the current quarter was $0.2
million compared to $5.8 million in the same prior year period.

Total revenues for the nine months ended September 30, 2009 were $3.74 billion
compared to $3.93 billion for the same prior year period. Included in total
revenues were other revenues of $61.1 million in the current year compared to
$493.8 million in the same prior year period. The prior year includes $468.1
million related to the sale of Bystolic. Excluding this, other revenue
increased by $35.5 million in the current year, primarily the result of
approximately $26.0 million of incremental revenue resulting from the
cancellation of certain product development agreements.

Net revenues for the nine months ended September 30, 2009, were $3.68 billion
compared to $3.44 billion in the same prior year period, an increase of $239.2
million or 7.0%. On a constant currency basis, year-over-year revenue growth
would have been approximately 14%.

Generics revenues were $3.41 billion in the nine months ended September 30,
2009, compared to $3.16 billion in the same prior year period.

Total revenues from North America were $1.64 billion for the nine months ended
September 30, 2009, compared to $1.31 billion for the same prior year period,
representing an increase of 24.7%. This increase was the result of new
product revenue of approximately $297.0 million, mainly Divalproex Sodium
Extended-Release tablets, Mylan's version of Abbott Laboratories' Depakote®
ER, and Levetiracetam, Mylan's version of UCB Pharma's Keppra®, and higher
volumes, partially offset by unfavorable pricing.

Mylan's Fentanyl Transdermal System (Fentanyl), Mylan's AB-rated generic
alternative to Duragesic®, continued to contribute significantly to both
revenue and gross profit despite the entrance into the market of additional
generic competition. Sales of Fentanyl have remained relatively strong
primarily due to Mylan's ability to continue to be a stable and reliable
source of supply to the market.

Total revenues from EMEA were $1.18 billion in the current nine month period,
compared to $1.27 billion in the prior year period, a decrease of 7.2%. On a
constant currency basis, EMEA revenues would have increased by approximately
5%. Increased revenues in France and Italy, and a full nine months of revenue
contribution from the Central and Eastern European businesses acquired in June
2008, served to offset lower revenues brought about by continued pricing
pressures in certain European markets, primarily in Germany.

Total revenues in Asia Pacific were $692.2 million in the current nine month
period, compared to $678.8 million in the prior year period, an increase of
2.0%. On a constant currency basis, sales in the current year increased by
approximately 15%. The increase in Asia Pacific was primarily realized by
Mylan's Japanese and Indian subsidiaries, and higher sales of API. These
increases were partially offset by lower sales in Australia, which were
negatively impacted by the government price reduction of 25% that took place
in the third quarter of 2008.

Specialty reported third party revenue of $353.0 million, an increase of $44.6
million or 14.4% from third party revenues of $308.5 million for the nine
months ended September 30, 2008. Increased sales of the EpiPen Auto-Injector
and Perforomist Solution in the current year were partially offset by lower
sales of DuoNeb® as a result of the unfavorable impact of generic competition,
which first entered the market in 2007.

Consolidated gross profit for the nine months ended September 30, 2009, was
$1.56 billion and gross margins were 41.7%, compared to gross profit of $1.68
billion and gross margins of 42.6% in the same prior year period. Excluding
Bystolic and the effect of certain purchase accounting related items described
above, which totaled $210.2 million and $335.7 million for the nine months
ended September 30, 2009 and 2008, gross margin was 47.3% in the current year
period, compared to 44.5% in the prior year period.

Earnings from operations were $463.3 million for the nine months ended
September 30, 2009, which included net unfavorable litigation charges of
$111.5 million. For the nine months ended September 30, 2008, earnings from
operations were $263.3 million, which included a non-cash goodwill impairment
charge of $385.0 million. Excluding these items, as well as the impact of the
Bystolic revenue in 2008 and the purchase accounting related items in both
periods, as mentioned above, earnings from operations for the nine months
ended September 30, 2009 were $785.1 million compared to $515.9 million for
the prior year, an increase of 52.2%.

This increase in operating income in the current year is due to increased
revenue and gross profit, as well as lower overall operating expenses, which
decreased as a result of the favorable effect of the stronger U.S. dollar and
by synergies realized as a result of the company's ongoing restructuring
initiatives. In addition, SG&A in the prior year included higher costs as a
result of a greater amount of activity associated with the integration of the
former Merck Generics business. Partially offsetting these favorable items
were increased professional fees in the current year as well as higher payroll
and payroll related costs.

Interest expense for the nine months ended September 30, 2009, totaled $240.2
million compared to $282.4 million for the nine months ended September 30,
2008. The decrease is due to the reduction of our outstanding debt balance,
through repayments made in December 2008 and March 2009, as well as lower
overall interest rates. Other income, net, for the nine months ended
September 30, 2009 was $29.7 million, versus $20.6 million for the same period
in the prior year.

EBITDA, which is defined as net income (loss) (excluding the non-controlling
interest and income from equity method investees) plus income taxes, interest
expense, depreciation and amortization, was $165.1 million for the quarter
ended September 30, 2009 and $791.1 million for the nine months then ended.
After adjusting for certain non-recurring or non-cash items as further
discussed below, adjusted EBITDA was $300.4 million and $942.1 million for the
three and nine months, respectively.

Cash provided by operating activities was $546.6 million for the nine months
ended September 30, 2009. Cash used in investing activities for the nine
months ended September 30, 2009 was $282.9 million, which consisted primarily
of approximately $172.0 million which was spent to acquire the additional
shares of Matrix and $38.9 million which was used to acquire an additional 50%
interest in a joint venture. Partially offsetting these cash outflows was the
receipt of $23.3 million consisting of the proceeds from the sale of a 50%
interest in another joint venture. Capital expenditures for the nine months
ended September 30, 2009 were $83.1 million. Cash used in financing
activities was $242.8 million for the nine months ended September 30, 2009,
which included cash dividends of $104.3 million paid on the Company's
preferred stock. Additionally, the Company made repayments on its long-term
debt in the amount of $153.3 million. These payments primarily consist of the
prepayment of amounts due in 2010 under the Company's Senior Credit Agreement.

Non-GAAP Financial Measures

Mylan is disclosing non-GAAP financial measures when providing financial
results. Primarily due to acquisitions, Mylan believes that an evaluation of
its ongoing operations (and comparisons of its current operations with
historical and future operations) would be difficult if the disclosure of its
financial results were limited to financial measures prepared only in
accordance with accounting principles generally accepted in the U.S. (GAAP).
In addition to disclosing its financial results determined in accordance with
GAAP, Mylan is disclosing non-GAAP results that exclude items such as
amortization expense and other costs directly associated with the acquisitions
as well as certain other non-recurring and non-cash expenses and revenue in
order to supplement investors' and other readers' understanding and assessment
of the company's financial performance because the company's management uses
these measures internally for forecasting, budgeting and measuring its
operating performance. In addition, the company believes that including EBITDA
and supplemental adjustments applied in presenting adjusted EBITDA is
appropriate to provide additional information to investors to demonstrate the
company's ability to comply with financial debt covenants (which are
calculated using a measure similar to adjusted EBITDA) and assess the
company's ability to incur additional indebtedness. Whenever Mylan uses such a
non-GAAP measure, it will provide a reconciliation of non-GAAP financial
measures to the most closely applicable GAAP financial measure. Investors and
other readers are encouraged to review the related GAAP financial measures and
the reconciliation of non-GAAP measures to their most closely applicable GAAP
measure set forth below and should consider non-GAAP measures only as a
supplement to, not as a substitute for or as a superior measure to, measures
of financial performance prepared in accordance with GAAP.

Below is a reconciliation of Mylan's results as reported under GAAP to its
adjusted results for the three and nine months ended September 30, 2009 (in
millions, except per share amounts):

Three Months Ended September 30, 2009
-----------------------------------------
As
GAAP Adjustments Adjusted
-------- --------------- ----------

Total revenues $1,264.1 $- $1,264.1
Cost of sales 759.1 (79.6) b 679.5
----- ----- -----

Gross profit 505.0 79.6 584.6

Operating expenses:
Research and
development 69.8 (0.3) a 69.5
Selling, general and
administrative 259.6 (9.7) a 249.9
Litigation
settlements, net 114.3 (114.3) -
----- ------ --
Total operating
expenses 443.7 (124.3) 319.4
----- ------ -----

Earnings from
operations 61.3 203.9 265.2
Interest expense 77.0 (10.8) d 66.2
Other income, net 0.2 (1.9) e (1.7)
--- ---- ----

(Loss) earnings
before income taxes
and noncontrolling
interest (15.5) 212.8 197.3
Income tax (benefit)
provision (11.1) 65.3 f 54.2
----- ---- ----

Net (loss) earnings (4.4) 147.5 143.1
Net earnings) loss
attributable
to the
noncontrolling
interest (0.8) - (0.8)
---- -- ----
Net (loss)
earnings
attributable to
Mylan Inc.
before preferred
dividends (5.2) 147.5 142.3
Preferred dividends 34.8 (34.8) h -
---- ----- --
Net (loss)
earnings
attributable to
Mylan Inc.
common
shareholders $(40.0) $182.3 $142.3
====== ====== ======

Diluted (loss) earnings
per common share
attributable to Mylan Inc.
common shareholders: $(0.13) $0.32
====== =====

Diluted weighted
average common
shares
outstanding: 305 140 h 445
=== === ===

Nine Months Ended September 30, 2009
----------------------------------------
As
GAAP Adjustments Adjusted
-------- --------------- ----------

Total revenues $3,741.0 $(30.8) a $3,710.2
Cost of sales 2,182.4 (228.8) b 1,953.6
------- ------ -------

Gross profit 1,558.6 198.0 1,756.6

Operating expenses:
Research and
development 202.7 (22.5) c 180.2
Selling, general and
administrative 781.0 (43.2) a 737.8
Litigation
settlements, net 111.5 (111.5) -
----- ------ --
Total operating
expenses 1,095.2 (177.2) 918.0
------- ------ -----

Earnings from
operations 463.4 375.2 838.6
Interest expense 240.2 (31.7) d 208.5
Other income, net 29.7 (25.7) e 4.0
---- ----- ---

(Loss) earnings
before income taxes
and noncontrolling
interest 252.9 381.2 634.1
Income tax (benefit)
provision 52.5 137.7 f 190.2
---- ----- -----

Net (loss) earnings 200.4 243.5 443.9
Net (earnings)
loss attributable
to the noncontrolling
interest (6.7) 3.0 g (3.7)
---- --- ----
Net (loss)
earnings
attributable to
Mylan Inc.
before preferred
dividends 193.7 246.5 440.2
Preferred dividends 104.3 (104.3) h -
----- ------ --
Net (loss)
earnings
attributable to
Mylan Inc.
common
shareholders $89.4 $350.8 $440.2
===== ====== ======

Diluted (loss) earnings
per common share
attributable to Mylan Inc.
common shareholders: $0.29 $0.97
===== =====

Diluted weighted
average common
shares
outstanding: 306 149 h 455
=== === ===

(a) This adjustment relates to integration and other non-recurring items,
which includes charges principally related to the acquisition and integration
of the former Merck Generics business (e.g., non-recurring professional and
consulting fees and other non-recurring expenses) as well as certain
restructuring and non-recurring revenue items, consisting primarily of the
acceleration of the recognition of revenue related to certain product
development agreements.

(b) This amount consists primarily of amortization expense related to
purchased intangible assets in the amount of $71.8 million and $210.2 million
for the three and nine months, respectively. The remainder in each period
relates to integration and other non-recurring items. See footnote (a).

(c) This amount includes a one-time charge related to an upfront payment made
with respect to the Company's execution of a co-development agreement, and
integration and other non-recurring items. See footnote (a).

(d) Represents non-cash interest on the Company's convertible notes.

(e) Included in this amount for the nine month period is a $13.9 million
favorable adjustment to the Company's restructuring reserve as a result of a
reduction in the estimated remaining spending on accrued projects and a gain
of approximately $10.4 million on the termination of two 50% owned joint
ventures with Aspen Pharmacare Holdings Limited of South Africa. The
remainder in each period relates to integration and other non-recurring items.
See footnote (a).

(f) The tax effect is calculated assuming an annual adjusted effective tax
rate for the resulting adjusted earnings, and results in a year-to-date
adjusted effective tax rate on adjusted earnings of 30% including the impact
of tax synergies.

(g) The gain of $10.4 million described in footnote (e) was recorded by the
Company's majority-owned subsidiary. As this gain was excluded from adjusted
earnings, an adjustment was recorded to also exclude from net earnings the
amounts attributable to the noncontrolling interest with respect to this gain.

(h) Adjusted diluted EPS for the three and nine months ended September 30,
2009, were calculated under the "if-converted method" which assumes conversion
of the company's preferred stock into 140.1 million and 148.6 million shares
of common stock, respectively, and excludes the preferred dividend from the
calculation. The "if-converted" method was more dilutive to adjusted diluted
EPS for the three and nine month periods by approximately $0.03 per share and
$0.13 per share, respectively.

Below is a reconciliation of GAAP net earnings attributable to Mylan Inc. to
adjusted EBITDA for the three and nine months ended September 30, 2009:

Three months Nine months
ended ended
September September
(in millions) 30, 2009 30, 2009
---------- ----------

GAAP net (loss) earnings
attributable to Mylan Inc. $(5.2) $193.7
Add/(Deduct):
Net contribution attributable to the
noncontrolling interest and equity
method investees 0.9 5.5
Income taxes (11.1) 52.5
Interest expense 77.0 240.2
Depreciation and amortization 103.5 299.2
----- -----
EBITDA 165.1 791.1
Add Adjustments:
Non-cash stock-based
compensation expense 8.9 23.6
Litigation settlements, net 114.3 111.5
Integration and other non-
recurring items 12.1 15.9
Adjusted EBITDA $300.4 $942.0
====== ======

Conference Call

Mylan will host a conference call and live webcast today, Thursday, October
29, 2009, at 10:00 a.m. ET, in conjunction with the release of its financial
results. The dial-in number to access the call is 877.874.1586 or
719.325.4775 for international callers. A replay, available for approximately
seven days, will be available at 888.203.1112 or 719.457.0820 for
international callers with access pass code 1742471. To access a live webcast
of the call, please log on to Mylan's Web site (www.mylan.com) at least 15
minutes before the event is to begin to register and download or install any
necessary software. A replay of the webcast will be available on www.mylan.com
for approximately seven days.

About Mylan
Mylan Inc. ranks among the leading generic and specialty pharmaceutical
companies in the world and provides products to customers in more than 140
countries and territories. The company maintains one of the industry's
broadest and highest quality product portfolios supported by a robust product
pipeline; operates the world's third largest active pharmaceutical ingredient
manufacturer; and runs a specialty business focused on respiratory and allergy
therapies. For more information, please visit www.mylan.com.

Forward Looking Statements
This press release includes statements that constitute "forward-looking
statements", including with regard to the company's future operations and its
earnings expectations. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Because
such statements inherently involve risks and uncertainties, actual future
results may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause or contribute to such
differences include, but are not limited to: challenges, risks and costs
inherent in business integrations and in achieving anticipated synergies; the
effect of any changes in customer and supplier relationships and customer
purchasing patterns; general market perception of the acquisition of the
former Merck Generics business; the ability to attract and retain key
personnel; changes in third-party relationships; the impacts of competition;
changes in economic and financial conditions of the company's business;
uncertainties and matters beyond the control of management; inherent
uncertainties involved in the estimates and judgments used in the preparation
of financial statements, and the providing of estimates of financial measures,
in accordance with GAAP and related standards. These cautionary statements
should be considered in connection with any subsequent written or oral
forward-looking statements that may be made by the company or by persons
acting on its behalf and in conjunction with its periodic SEC filings. In
addition, please refer to the cautionary statements and risk factors set forth
in the company's Report on Form 10-Q, for the quarter ended June 30, 2009, and
in its other filings with the SEC. Further, uncertainties or other
circumstances, or matters outside of the company's control between the date of
this release and the date that its Form 10-Q for the quarter ended September
30, 2009 is filed with the SEC could potentially result in adjustments to
reported results. The company undertakes no obligation to update statements
herein for revisions or changes after the date of this release.

Mylan Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(Unaudited; in thousands, except per share amounts)

Period Ended September 30,
--------------------------
Three Months Nine Months
------------ -----------
2009 2008 2009 2008
---- ---- ---- ----
As As
Adjusted* Adjusted*
Revenues:
Net revenues $1,255,708 $1,191,010 $3,679,868 $3,440,680
Other revenues 8,366 465,838 61,100 493,750
----- ------- ------ -------

Total revenues 1,264,074 1,656,848 3,740,968 3,934,430
Cost of sales 759,094 745,711 2,182,488 2,258,863
------- ------- --------- ---------

Gross profit 504,980 911,137 1,558,480 1,675,567
------- ------- --------- ---------

Operating expenses:
Research and
development 69,812 74,721 202,665 239,320
Impairment
loss on
goodwill - - - 385,000
Selling, general
and
administrative 259,609 275,584 780,953 787,953
Litigation
settlements,
net 114,281 - 111,530 -
------- --- ------- ---
Total
operating
expenses
443,702 350,305 1,095,148 1,412,273
------- ------- --------- ---------
Earnings from
operations
Interest expense 61,278 560,832 463,332 263,294
Other income, net 77,034 93,540 240,209 282,405
243 5,766 29,741 20,583
--- ----- ------ ------
(Loss) earnings
before income
taxes and
noncontrolling
interest
Income tax
(benefit)
provision (15,513) 473,058 252,864 1,472
(11,092) 256,088 52,539 180,062
------- ------- ------ -------
Net (loss) earnings
Net (earnings)
loss attributable to
the noncontrolling
interest (4,421) 216,970 200,325 (178,590)
Net (loss)
earnings
attributable to
Mylan Inc.
before preferred
dividends (841) 151 (6,658) 2,266
---- --- ------ -----
Preferred dividends (5,262) 217,121 193,667 (176,324)
Net (loss)
earnings
attributable to
Mylan Inc.
common
shareholders 34,759 34,759 104,276 104,236
------ ------ ------- -------
$(40,021) $182,362 $89,391 $(280,560)
======== ======== ======= =========
(Loss) earnings
per common
share
attributable
to Mylan Inc.
common
shareholders:
Basic
Diluted $(0.13) $0.60 $0.29 $(0.92)
====== ===== ===== ======
$(0.13) $0.47 $0.29 $(0.92)
====== ===== ===== ======
Weighted average
common shares
outstanding:
Basic 305,285 304,449 304,951 304,305
======= ======= ======= =======
Diluted 305,285 458,350 306,086 304,305
======= ======= ======= =======

* Adjusted to reflect the adoption of FSP APB No. 14-1

Mylan Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited; in thousands)

September 30, 2009 December 31, 2008
------------------ -----------------
As Adjusted*
Assets:
Current assets:
Cash and cash
equivalents $584,411 $557,147
Restricted cash 63,346 40,309
Available-for-sale
securities 34,034 42,260
Accounts receivable,
net 1,102,380 1,164,613
Inventories 1,119,042 1,065,990
Other current assets 358,716 304,354
------- -------
Total current
assets 3,261,929 3,174,673
Intangible assets, net 2,465,869 2,453,161
Goodwill 3,316,654 3,161,580
Other non-current
assets 1,718,116 1,620,445
--------- ---------
Total assets $10,762,568 $10,409,859
=========== ===========

Liabilities:
Current liabilities $1,583,336 $1,544,650
Long-term debt 5,128,827 5,078,937
Other non-current
liabilities 978,513 999,431
------- -------
Total liabilities 7,690,676 7,623,018
Noncontrolling interest 13,057 29,108
Mylan Inc. shareholders'
equity 3,058,835 2,757,733
--------- ---------
Total liabilities and
equity $10,762,568 $10,409,859
=========== ===========

* Adjusted to reflect the adoption of FSP APB No. 14-1

SOURCE Mylan Inc.

Michael Laffin (Media), +1-724-514-1968, or Dan Crookshank (Investors),
+1-724-514-1813